(2024-2033) Non-Proliferative Diabetic Retinopathy Market Size, Share, Trends, Industry Growth Analysis and Forecast | Samsung Electronics Co. Ltd., Dell Technologies Inc., Huawei Technologies Co. Ltd., Accenture Inc.

Overview and Scope
Non-proliferative diabetic retinopathy (NPDR) is a common complication of diabetes mellitus that affects the retina, the light-sensitive tissue lining the back of the eye. NPDR is characterized by changes in the blood vessels of the retina due to prolonged exposure to high levels of blood sugar (hyperglycemia) associated with diabetes. It is managed through a combination of medical interventions, lifestyle modifications, and regular eye examinations to prevent disease progression and preserve vision.

Sizing and Forecast
The non-proliferative diabetic retinopathy market size has grown strongly in recent years. It will grow from $2.43 billion in 2023 to $2.62 billion in 2024 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increased prevalence of diabetes, aging population, improved awareness, research advancements, lifestyle changes and improved diabetes management.

The non-proliferative diabetic retinopathy market size is expected to see strong growth in the next few years. It will grow to $3.58 billion in 2028 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to adoption of telemedicine, development of novel therapeutics, integration of artificial intelligence, increasing investments in research and development, and expansion of healthcare infrastructure. Major trends in the forecast period include increasing adoption of artificial intelligence for screening and diagnosis, rising demand for telemedicine and remote monitoring solutions, emergence of, personalized medicine approaches for diabetic retinopathy treatment, growing focus on preventive strategies and early intervention, and expanding role of patient-centered care models in managing diabetic retinopathy.

Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/non-proliferative-diabetic-retinopathy-global-market-report

The non-proliferative diabetic retinopathy market covered in this report is segmented –

1) By Treatment Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Intraocular Steroid Injection, Laser Surgery, Vitrectomy
2) By Disease Severity Level: Mild Non-Proliferative Diabetic Retinopathy, Moderate Non-Proliferative Diabetic Retinopathy, Severe Non-Proliferative Diabetic Retinopathy
3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End-Users

North America was the largest region in the non-proliferative diabetic retinopathy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-proliferative diabetic retinopathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=15620&type=smp

Major Driver Impacting Market Growth
The increasing prevalence of diabetes is expected to propel the growth of the non-proliferative diabetic retinopathy market going forward. Diabetes is a chronic metabolic disorder characterized by elevated blood glucose (blood sugar) due to inadequate production of insulin by the pancreas or the body’s cells becoming resistant to the effects of insulin. Diabetes is caused due to sedentary lifestyles, unhealthy dietary habits, and genetic predispositions. Diabetes induces non-proliferative diabetic retinopathy by damaging the blood vessels in the retina, primarily due to prolonged exposure to high levels of glucose in the bloodstream, resulting in vision impairment and potential blindness. For instance, in November 2021, according to the International Diabetes Federation, a Belgium-based umbrella organization of diabetes associations, approximately 537 million adults (20–79 years old) were living with diabetes in 2021. In contrast, the total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. Therefore, the increasing prevalence of diabetes is driving the growth of the non-proliferative diabetic retinopathy market.

Key Industry Players
Major companies operating in the non-proliferative diabetic retinopathy market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc. , Bayer AG, Abbott Laboratories, Novartis AG, Eli Lilly and Company, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Genentech Inc., Carl Zeiss Meditec AG, ZEISS Group, Santen Pharmaceutical Co. Ltd., Santen Inc., Topcon Corporation, Lumenis Ltd., Alimera Science, Ocular Therapeutix Inc., Acucela Inc., Ampio Pharmaceuticals, Kowa Company Ltd., Nidek Co. Ltd.

The non-proliferative diabetic retinopathy market report table of contents includes:

1. Executive Summary

2. Non-Proliferative Diabetic Retinopathy Characteristics

3. Non-Proliferative Diabetic Retinopathy Trends And Strategies

4. Non-Proliferative Diabetic Retinopathy – Macro Economic Scenario

5. Global Non-Proliferative Diabetic Retinopathy Size and Growth

…..

32. Global Non-Proliferative Diabetic Retinopathy Competitive Benchmarking

33. Global Non-Proliferative Diabetic Retinopathy Competitive Dashboard

34. Key Mergers And Acquisitions In The Non-Proliferative Diabetic Retinopathy

35. Non-Proliferative Diabetic Retinopathy Future Outlook and Potential Analysis

36. Appendix